Is there a benefit of first- or second-line crizotinib in locally advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer? a meta-analysis

BACKGROUND: Crizotinib show a promising efficacy in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). However, differences in efficacy for first- and second-line crizotinib are unclear. RESULTS: The pooled overall response rate and progression-free survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Hao, Lin, Wei Qing, Zhu, Qian, Yang, Xiong Wen, Wang, Hai Dong, Kuang, Yu Kang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348378/
https://www.ncbi.nlm.nih.gov/pubmed/27835601
http://dx.doi.org/10.18632/oncotarget.13191

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348378/
https://www.ncbi.nlm.nih.gov/pubmed/27835601
http://dx.doi.org/10.18632/oncotarget.13191

Ejemplares similares